-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Soleno Therapeutics, Raises Price Target to $114

Benzinga·01/20/2026 15:51:44
Listen to the news
Wells Fargo analyst Derek Archila maintains Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and raises the price target from $106 to $114.